The histone 3 lysine 9 methyltransferase inhibitor chaetocin improves prognosis in a rat model of high salt diet-induced heart failure

Tomohiko Ono, Naomi Kamimura, Tomohiro Matsuhashi, Toshihiro Nagai, Takahiko Nishiyama, Jin Endo, Takako Hishiki, Tsuyoshi Nakanishi, Noriaki Shimizu, Hirotoshi Tanaka, Shigeo Ohta, Makoto Suematsu, Masaki Ieda, Motoaki Sano, Keiichi Fukuda & Ruri Kaneda

Histone acetylation has been linked to cardiac hypertrophy and heart failure. However, the pathological implications of changes in histone methylation and the effects of interventions with histone methyltransferase inhibitors for heart failure have not been fully clarified. Here, we focused on H3K9me3 status in the heart and investigated the effects of the histone H3K9 methyltransferase inhibitor chaetocin on prognoses in Dahl salt-sensitive rats, an animal model of chronic heart failure. Chaetocin prolonged survival and restored mitochondrial dysfunction. ChIP-seq analysis demonstrated that chronic stress to the heart induced H3K9me3 elevation in thousands of repetitive elements, including intronic regions of mitochondria-related genes, such as the gene encoding peroxisome proliferator-activated receptor-gamma coactivator 1 alpha. Furthermore, chaetocin reversed this effect on these repetitive loci. These data suggested that excessive heterochromatinization of repetitive elements of mitochondrial genes in the failing heart may lead to the silencing of genes and impair heart function. Thus, chaetocin may be a potential therapeutic agent for chronic heart failure.

Heart failure is one of the leading causes of death worldwide. Although existing heart failure therapies that target the renin-angiotensin-aldosterone and adrenergic nervous systems are effective, mortality from heart failure remains high. Novel insights into the mechanisms underlying this disease are necessary to establish a more effective therapeutic strategy. Mitochondria and metabolic function have been targeted for the treatment of heart failure because they are essential for myocardial energy production, cell redox potential, reactive oxygen species (ROS) generation, mitochondria-dependent apoptosis, calcium homeostasis, and fatty acid and glucose metabolism.

Pathological hypertrophy and heart failure are associated with altered expression of a number of genes. Asakura et al. reported that many heart failure-related genes are involved in the pathways of mitochondrial function, oxidative phosphorylation, and extracellular signaling. Epigenetic alterations play an important role in the regulation of transcriptional activity. Histone modifications can alter chromatin structure to influence

1Department of Cardiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. 2Department of Biochemistry and Cell Biology, Institute of Development and Aging Sciences, Graduate School of Medicine, Nippon Medical School, Kawasaki, Kanagawa, Japan. 3Electron Microscope Laboratory, Keio University Hospital, Shinjuku-ku, Tokyo, Japan. 4Department of Biochemistry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. 5MS Business Unit, Shimadzu Corporation, Kyoto, Japan. 6Division of Rheumatology, Center for Antibody and Vaccine Therapy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan. 7Division of Anti-aging Medicine, Center for Molecular Medicine, Jichi Medical University, Shimotsukeshi, Tochigi, Japan. 8Division of Anti-aging Medicine, Center for Molecular Medicine, Jichi Medical University, Shimotsukeshi, Tochigi, Japan. 9Division of Rheumatology, Center for Antibody and Vaccine Therapy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan. 10Division of Anti-aging Medicine, Center for Molecular Medicine, Jichi Medical University, Shimotsukeshi, Tochigi, Japan. 11ST, PRESTO, Kawaguchi, Saitama, Japan. 12Clinical and Translational Research Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. Correspondence and requests for materials should be addressed to K.F. (email: kfuuka@aa2.keio.jp) or R.K. (email: rurikaneda@jichi.ac.jp)
transcription factor access to the DNA and the recruitment of transcriptional complexes to gene promoter/ enhancer regions35. Histone acetylation and deacetylation are known to play a role in the development of cardiac hypertrophy and heart failure36,37. Furthermore, inhibition of histone deacetylase (HDAC) activity prevents cardiac remodeling38. HDAC inhibitors are likely to have multiple mechanisms of efficacy39, including inhibition of cardiac hypertrophy20,21, autophagy22, apoptosis23, cardiac fibrosis40,41, inflammation42,43, and regulation of cardiac contractility44.

We have previously shown that the chromosomal distributions of histone H3 lysine 9 trimethylation (H3K9me3) and histone H3 lysine 4 trimethylation (H3K4me3) rather than that of histone acetylation differ between the normal and failed heart in animal models of heart failure28. Additional evidence suggests that histone methylation on lysine 4 (K4), K9, or K36 of histone H3 are involved in cardiac remodeling30–33. Therefore, both histone methylation and histone acetylation may act as therapeutic targets for the management of heart failure.

H3K9me3 is associated with heterochromatin formation and is required to establish the pericentromere and telomere regions34. Alterations in H3K9me3 levels at various genomic loci, including satellite repeats and repetitive transposable elements, are also associated with cancer and stress responses35,36. However, neither the role of H3K9me3 on repetitive loci in the failing heart nor the efficacy of histone methyltransferase inhibitors in heart failure has been clarified.

Therefore, in this study, we investigated H3K9 trimethylation status on repetitive elements in the failing heart and hypothesized that the histone-modifying enzyme affecting H3K9 trimethylation status may play an important role in heart failure. SU(VAR)3-9 is an enzyme that catalyzes the conversion of K9 in histone H3 from a dimethylated form to a trimethylated form. Chaetocin, a natural small molecule produced by fungi of the Chaetomium species37, is an inhibitor of SU(VAR)3-9. Thus, we investigated whether this H3K9 methyltransferase inhibitor blocked the progression of heart failure in an animal model. In this study, we showed that chaetocin delayed the transition from hypertrophy to heart failure, restored mitochondrial dysfunction in failing hearts, and prolonged animal survival.

**Results**

**Chaetocin improved the prognosis of Dahl salt-sensitive (DS) rats with heart failure.** A high-salt diet in DS rats induced hypertension, leading to left ventricular (LV) hypertrophy and heart failure at around 13 weeks. The blood pressures of animals consuming a high-salt diet were high, regardless of chaetocin administration (Fig. 1A). At the age of 13 weeks, the body weights of animals fed a high-salt diet were lower than those of animals fed a normal-salt diet (Supplemental Fig. 1). Heart weight/weight ratios were higher in the heart failure (HF) group [high-salt diet containing 8% NaCl, HS (−)] than in the control group [normal-salt diet containing 0.3% NaCl, NS (−)]. The increases in LV/BW ratios in rats consuming the high-salt diet were not significantly reversed by administration of chaetocin [high-salt diet with 0.25 mg/kg of chaetocin, HS (ch+); Fig. 1B].

The expression of the gene encoding *natriuretic peptide precursor A (Nppa)*, a marker of heart failure, was upregulated in LV tissues in the HF group, and this increase in expression was significantly suppressed by chaetocin administration (Fig. 1C). To determine whether chaetocin could improve cardiac function, we performed echocardiographic studies in 13-week-old rats. LV systolic function, represented by fractional shortening (FS), was significantly improved following treatment with chaetocin. Additionally, LV posterior wall thickness was not changed following chaetocin treatment (Fig. 1D). These data indicated that chaetocin did not affect the development of cardiac hypertrophy, but did maintain LV systolic function. To assess the influence of chaetocin on cardiac fibrosis, we examined cardiac tissues microscopically. Fibrotic areas were detected using Elastica van Gieson (EvG) stain with picrosirius red staining of sectioned tissue. The fibrotic area tended to be larger in the HF group than in the control group, and administration of chaetocin tended to reduce cardiac fibrosis (Fig. 1E). The survival rate was significantly improved by treatment with chaetocin (Fig. 1F). These data suggested that chaetocin improved the prognosis of DS rats with heart failure by delaying the transition from hypertrophy to heart failure.

**Chaetocin restored the downregulation of mitochondria-related genes in heart failure.** To determine the mechanisms underlying the effects of chaetocin, we used DNA microarray analysis in LV tissues of DS rats. Chaetocin is an inhibitor of SU(VAR)3-9 methyltransferase activity38. Therefore, we focused on genes whose expression levels decreased in failing hearts and were restored with chaetocin treatment. Fifty genes were identified based on the following criteria: (1) the ratio of gene expression in the HF group to that in the control group was less than 0.5; (2) the ratio of gene expression in the treatment group to that in the HF group was greater than 1.4; (3) the normalized expression level in the HF group was equal to or greater than 100 (Table 1).

The “Mitochondrion” was identified as the gene ontology (GO) term with the smallest Hyp* value by singular enrichment analysis of the “cellular component” category in the GeneCodis3 database (http://genecodis.cnb.csic.es/release/) using the set of 50 genes shown in Table 1 (Fig. 2A). Therefore, we focused on mitochondrial function. Detailed results for the GO analyses of the 50 identified genes are given in Supplemental Tables 3 and 4.

**Chaetocin improved mitochondrial respiration and increased the mitochondrial content in failing hearts.** To investigate whether chaetocin improved mitochondrial function, we measured mitochondrial respiration with pyruvate/malate as an energy source. Respiration states (2–4) and uncoupled respiration rates were calculated as nmol of oxygen/min/mg of mitochondrial protein. State 3 and uncoupled respiration of mitochondria isolated from rats in the HS (ch+) group tended to be higher than that from rats in the HS (−) group, although statistical significance was never reached (p > 0.1). Importantly, in every mitochondrial preparation, a small amount of contaminants from other organelles and debris may be present and contribute to the overall protein concentration. Moreover, mitochondrial preparations from damaged tissue may be unstable and cause variability in the data when the same amount of protein is used for each respiration assay. Respiratory control
Figure 1. Chaetocin improved the prognosis of rats in a model of heart failure. (A) Systolic and diastolic blood pressures (SBP and DBP, respectively). (B) Heart weight/body weight (HW/BW) ratios are shown for 13-week-old rats in the control group [NS (−), n = 11], normal salt diet with chaetocin group [NS (ch+), n = 7], HF group [HS (−), n = 17], and treatment group [HS (ch+), n = 17]. (C) Quantitative real-time PCR analysis of natriuretic peptide precursor A (Nppa, ANP) mRNA expression in left ventricular tissues for 13-week-old rats in the control group (n = 5), normal salt diet with chaetocin group (n = 4), HF group (n = 10), and treatment group (n = 14). (D) Echocardiographic measurements of fractional shortening (FS) and posterior wall thickness (PWT). (E) Hematoxylin-eosin-stained (upper panel, scale bars: 2 mm) or Elastica van Gieson (EvG) with picrosirius red-stained sections of cardiac tissue (middle panel, scale bars: 200 μm) and quantification of the fibrotic area (lower bar). (F) Kaplan-Meier survival analysis of DS rats in the control group (n = 9), normal salt diet with chaetocin group (n = 12), HF group (n = 17), and treatment group (n = 13). Data are presented as the mean ± SD. *P < 0.05 and **P < 0.01 versus the control group; †P < 0.05 and ††P < 0.01 versus the HF group; †P < 0.05 and ††P < 0.01 versus the normal salt diet with chaetocin group; n.s.: not significant.
| Ensembl ID | RefSeq_ID | Symbol | Description | GO | Ratio |
|------------|-----------|--------|-------------|----|-------|
| ENSRNOG00000025757 NM_017239.1 | Myh6 | Myosin-6 (myosin heavy chain 6) (MyHC-alpha) | | Mitochondrion HS (−)/NS (−) HS (ch−)/HS (ch−) |
| ENSRNOG00000026548 XM_001078936.1 XM_213343.4 | Dhrs7c | N/A | | 0.2 1.59 |
| ENSRNOG00000012343 NM_145091.4 | Pdp2 | Pyruvate dehydrogenase (lipoyl) phosphatase 2, mitochondrial precursor (PDP2) | | 0.27 1.89 |
| ENSRNOG00000026679 NM_001008880.1 Snc4b | Sodium channel subunit beta-4 precursor | 0.3 1.51 |
| ENSRNOG00000006444 XM_001066628.1 XM_342763.3 | Flrk4 | FK506-binding protein 4 | 0.32 1.6 |
| ENSRNOG0000004078 NM_012949.2 Eno3 | Beta-enolase (enolase 3) | 0.33 1.77 |
| ENSRNOG00000015904 NM_133581.1 Wfcd1 | WAP four-disulfide core domain protein 1 precursor | 0.34 1.59 |
| ENSRNOG00000007290 NM_012505.1 Atp1a2 | Sodium/potassium-transporting ATPase subunit alpha-2 precursor | 0.34 1.45 |
| ENSRNOG00000004377 NM_001012111.1 Lpin1 | Lipin 1 | 0.34 1.46 |
| ENSRNOG00000002827 NM_001106974.2 NM_012949.2 Eno3 | Beta-enolase (enolase 3) | 0.35 1.69 |
| ENSRNOG00000018735 NM_013069.2 Cd74 | H-2 class II histocompatibility antigen gamma chain (CD74 antigen) | 0.36 1.85 |
| ENSRNOG00000026679 NM_001008880.1 Snc4b | Sodium channel subunit beta-4 precursor | 0.37 1.54 |
| ENSRNOG00000021174 NM_139337.1 Lrp16 | MACRO domain-containing protein 1 (protein LRP16) | 0.38 1.79 |
| ENSRNOG00000011260 NM_001008770.3 RGDC1306952 | Carboxymethylenebutenolidase homolog (liver regeneration-related protein LRRG072) | 0.39 1.54 |
| ENSRNOG00000015897 NM_001006940.1 Eno3 | Beta-enolase (enolase 3) | 0.4 1.57 |
| ENSRNOG00000009215 NM_001006959.1 Eno3 | Beta-enolase (enolase 3) | 0.4 1.71 |
| ENSRNOG00000003615 N/A | NU3M_RAT | Mitochondrial protein, 18 kDa | 0.41 1.57 |
| ENSRNOG00000003977 NM_057186.1 Hadhsc | Hydroxacyl-CoA dehydrogenase, mitochondrial precursor | 0.41 1.47 |
| ENSRNOG000000021091 NM_001075518.1 XM_227690.4 Ppa2 | N/A | 0.42 1.66 |
| ENSRNOG00000003924 XM_001077221.1 LOC691211 | N/A | 0.42 2.24 |
| ENSRNOG000000014128 NM_001006986.1 MGC94604 | Mitochondrial protein, 18 kDa | 0.43 1.71 |
| ENSRNOG000000033615 N/A | NU3M_RAT | Mitochondrial protein, 18 kDa | 0.43 1.57 |
| ENSRNOG00000002916 NM_001006960.1 Eno3 | Beta-enolase (enolase 3) | 0.43 1.71 |
| ENSRNOG00000003917 NM_001008770.3 RGDC1306952 | Carboxymethylenebutenolidase homolog (liver regeneration-related protein LRRG072) | 0.43 1.54 |
| ENSRNOG00000015807 NM_001004261.1 RGD1303232 | Probable oxidoreductase C10orf33 homolog | 0.45 1.86 |
| ENSRNOG00000002272 NM_001101828.1 RGD1306739 | Ligand of numb protein X1 | 0.45 1.65 |
| ENSRNOG00000012873 NM_001075518.1 XM_227690.4 Ppa2 | N/A | 0.45 1.96 |
| ENSRNOG00000003924 XM_001077221.1 LOC691211 | N/A | 0.45 1.71 |
| ENSRNOG00000014128 NM_001006986.1 MGC94604 | Mitochondrial protein, 18 kDa | 0.46 1.93 |
| ENSRNOG00000002916 NM_001006960.1 Eno3 | Beta-enolase (enolase 3) | 0.47 1.54 |
| ENSRNOG00000002916 NM_001006960.1 Eno3 | Beta-enolase (enolase 3) | 0.47 1.65 |
| ENSRNOG00000002272 NM_001101828.1 RGD1306739 | Ligand of numb protein X1 | 0.47 1.71 |
| ENSRNOG000000037446 NM_001006960.1 Eno3 | Beta-enolase (enolase 3) | 0.49 1.54 |
| ENSRNOG000000021866 NM_001006960.1 Eno3 | Beta-enolase (enolase 3) | 0.49 1.61 |
| ENSRNOG000000018516 NM_172224.1 Impa2 | Inositol monophosphatase 2 (IMPase 2) | 0.49 1.71 |
| ENSRNOG000000013352 NM_017328.1 Pgam2 | Phosphoglycerate mutase 2 | 0.49 1.93 |
| ENSRNOG000000031321 XR_007906.1 XR_006141.1 LOC63987 | N/A | 0.49 1.93 |
| ENSRNOG000000021812 XM_001060414.1 XM_001072661.1 LOC684826 | N/A | 0.49 1.93 |
| ENSRNOG000000016369 NM_001006966.1 Peci | Peroxisomal delta3, delta2-ensylcoenzyme A isomerase | 0.49 2.09 |
| ENSRNOG000000006108 XM_001075781.1 XM_001081328.1 LOC690825 | N/A | 0.49 2.09 |
| ENSRNOG000000016603 NM_001052543.1 Adhfe1 | Alcohol dehydrogenase, iron containing, 1 | 0.49 1.54 |
| ENSRNOG000000017446 NM_001106322.1 NADH dehydrogenase (ubiquinone) Fe-S protein 8 | N/A | 0.49 1.54 |

Continued
Table 1. DNA microarray analysis of LV tissue of DS rats. GO: gene ontology; NS (−), normal salt diet without chaetocin; HS (−), high-salt diet without chaetocin; HS (ch+), high-salt diet with chaetocin.

| Ensembl ID | RefSeq_ID | Symbol | Description | GO | GO Ratio | Mitochondrion | HS (−)/ NS (−) | HS (ch+)/ HS (−) |
|------------|-----------|--------|-------------|----|---------|---------------|---------------|----------------|
| ENSRN00000015519 | NM_001013889.1;XM_001079984.1 | Chpt1 | Cholinephosphotransferase 1 (diacylglycerol cholinephosphotransferase 1) | 0.49 | 1.58 | 0.49 | 1.58 |
| ENSRN00000015519 | NM_133295.3 | Ces3 | Carboxylesterase 3 precursor | 0.49 | 1.84 | 0.49 | 1.84 |

Heart failure increased H3K9me3 levels on repetitive elements, and this effect was reversed following chaetocin treatment. To investigate H3K9me3 status in the whole genome, including repetitive elements in the heart, we performed chromatin immunoprecipitation (ChIP) for analysis of sequences exhibiting H3K9me3 in the failed LV with or without chaetocin treatment and in controls. At 6550 loci associated with repetitive elements, heart failure caused an increase in H3K9me3 alignment compared with that in control samples. We defined these elements as “HF-up.” Ninety-nine percent of HF-up loci, i.e., 6534 repetitive elements, showed a corresponding reduction in H3K9me3 in response to chaetocin treatment. In contrast, at 335 loci, we observed a reduction in H3K9me3 alignment in the failing heart compared with that in the controls. We defined these elements as “HF-down.” Administration of the inhibitor reversed this effect for 10.4% of these HF-down loci, i.e., 35 repetitive elements (Fig. 3A). Thus, HF increased H3K9me3 levels on repetitive elements, and chaetocin altered H3K9me3 levels in those loci, as expected based on the inhibitory activity of H3K9 methyltransferase in heart tissues.

Chaetocin reduced H3K9me3 levels on intronic repetitive elements of Pgc1α. In this study, we focused on genomic regions in close proximity to RefSeq genes. Two repetitive loci in the intron of Pgc1α exhibited elevated H3K9me3 levels in the failing heart, and this effect was suppressed by chaetocin treatment (Fig. 3B). The other repetitive loci exhibiting elevated H3K9me3 levels in the failing heart included several genomic regions located in close proximity to mitochondrial genes. For example, we identified the following gene regions: an intron of Acyl-CoA dehydrogenase, medium-chain, Acadm (Fig. 4A); two intronic regions of NADH-ubiquinone oxidoreductase Fe-S protein 4, Ndufs4 (Fig. 4B); and a region in an intron for hexaprenyldihydroxybenzoate methyltransferase, mitochondrial precursor, Coq3 (Supplemental Fig. 2). Consistent with the H3K9me3 epigenetic profile, the mRNA levels of Acadm and Ndufs4 were reciprocally lowest in the failing heart, as judged from quantitative real-time PCR. Although the restoration of Coq3 mRNA with treatment was not significant, elevated H3K9me3 in the failing heart compared with that in the control heart may have contributed to down-regulation of Coq3 expression.

GO analyses of “HF-up” H3K9me3 repetitive loci reversed by chaetocin. The ratio of the length of repetitive sequences to the genomic length of whole RefSeq genes, including 10 kb up- or down-stream of those genes, was 31.905%. Additionally, the ratio of the genomic regions for genes categorized as “mitochondrion” was 31.791%. These data suggested that the length of repetitive sequences relative to the genome was not different between whole RefSeq genes and genes categorized as “mitochondrion.” A total of 2588 regions identified as showing the “HF-up” H3K9me3 loci reversed by chaetocin on any RefSeq gene or within 10 kb up- or down-stream of those genes were registered within GeneCodis3. Of those regions, the number of genes categorized as “mitochondrion” was 161 (6.2%). The number of whole RefSeq genes of the rat genome on GeneCodis3 was 29516. Of these genes, the number of genes categorized as “mitochondrion” by GO analysis was 1247 (4.2%). Therefore, enrichment of the “HF-up” H3K9me3 repetitive loci reversed by chaetocin to the GO “mitochondrion” was 1.47-fold greater than that observed by chance. The Hyp* value was 0.000000651241. These regions of the
“HF-up” H3K9me3 repetitive loci reversed by chaetocin included the intronic regions of Acadm, Ndufs4, and Coq3.

In conclusion, these data suggested that chronic stress to the heart caused excessive heterochromatinization on repetitive elements, including regions neighboring mitochondrial genes, such as Pgc1α, thereby decreasing the expression of the target genes and leading to mitochondrial dysfunction. H3K9 methyltransferase inhibitors may have promising applications as novel therapies for chronic heart failure by reducing excess heterochromatinization at repetitive regions in the genome and restoring heart function.

Discussion

In this study, we demonstrated that the histone H3K9 methyltransferase inhibitor chaetocin blocked the progression of heart failure and alleviated mitochondrial dysfunction. This epigenetic treatment may improve outcomes in patients with heart failure.

Alterations in H3K9me3 levels at various genomic loci, including satellite repeats and repetitive transposable elements, have been shown to be associated with cancer and stress responses; therefore, we focused on the...
Hunter et al. reported that “acute” stress increases H3K9me3 levels of a transposable element and that H3K9me3 suppresses the stress-induced activation of repetitive and transposable elements as a protective response. In contrast, Chan et al. found that GAA-triplet intronic expansions stimulate heterochromatinization and cause transcriptional repression of the Frataxin gene, leading to Friedreich's ataxia. Furthermore, Asano et al. suggested that products of intron-processed retroposons of the laminin receptor 1 gene interact with heterochromatin protein 1 (HP1) to cause degeneration of cardiomyocytes. Consistent with a previous study, stress to the heart may have induced H3K9 methylation of repetitive elements in intronic regions in our study. Based on the previous two reports, heterochromatinization of repetitive elements around critical genes or the formation of heterochromatin with HP1 may contribute to the pathophysiology of chronic heart failure. The Pgc1α gene, which we identified as “HF-up” and was found to exhibit restored H3K9me3 levels after chaetocin treatment, plays a key role in mitochondrial biogenesis and energy production. In addition to Pgc1α, we identified other genes that were related to mitochondrial function in this study.

**Figure 3.** Heart failure increased H3K9me3 levels on repetitive elements. (A) Number of repetitive elements in which heart failure caused an increase (HF-up) or decrease (HF-down) in H3K9me3 compared with control samples (left). The restoration percentage of H3K9 trimethylation state following treatment with chaetocin (right). (B) H3K9me3 levels in the intronic repetitive regions of Pgc1α. Red squares indicate the region that was identified as being enriched in H3K9me3 repetitive elements in rats with heart failure. The black boxes indicate the repetitive loci. The bars indicate the H3K9me3 read alignments of the repetitive elements. RPM, reads per million mapped.
Furthermore, we speculate that the discrepancy between the complete change in H3K9me3 in response to chaetocin in the repetitive elements of \( Pgc1\alpha \) and the smaller restoration of \( Pgc1\alpha \) gene expression may be explained by the occurrence of H3K9me3 and other epigenetic modifications during the progression and development of hypertrophy/heart failure. For example, histone deacetylation and DNA methylation at the promoter region may have occurred. Additional administration of the HDAC inhibitor may be more effective at restoring mRNA expression to basal levels.

Our results suggested that chronic stress to the heart may gradually promote excessive heterochromatinization at repeats in the introns of critical genes for pumping function, such as genes related to mitochondrial function. The H3K9 methyltransferase inhibitor chaetocin may maintain the appropriate chromatin structure and reverse the excessive heterochromatinization. Therefore, histone H3K9 methyltransferase inhibitors may represent potential novel therapies for chronic heart failure. Moreover, although chaetocin was initially identified as the first specific inhibitor of SU(VAR)3-9\(^{38}\), a recent report from another laboratory showed that it may not exhibit high

**Figure 4.** Representative data showing enrichment of H3K9me3 repetitive loci in regions in close proximity to \( Acadm \) (A) and \( Ndufs4 \) (B) in the HF group. Red squares indicate the region that was identified as being enriched in H3K9me3 repetitive elements in rats with heart failure. The black boxes indicate the repetitive loci. The blue bars indicate H3K9me3 read alignments. The mRNA level of each gene was determined with the real-time quantitative PCR and is shown as the fold change versus the control group. **\( P < 0.01 \) versus the control group; \#\( P < 0.05 \) and ##\( P < 0.01 \) versus the HF group.
The disulfide bridge of the epipolythiodioxopiperazine (ETP) unit may have a central role in mediating the histone lysine methyltransferase inhibitory activity of chaetocin through a nonspecific mechanism. Other ETP natural products can also inhibit histone lysine methyltransferases. Thus, it will be important to investigate whether other ETP products have similar effects on improving the prognosis of heart failure. Moreover, further experiments are needed to determine which histone lysine methyltransferase activity is inhibited by chaetocin in this model. In addition, as we cannot exclude the possibility that improvement of cardiac function by chaetocin caused the restoration of mitochondrial function-related gene expression, additional experiments using techniques, such as knockdown of Su(var)3–9, are required in order to show that alterations of H3K9me3 level or those of expression in mitochondrial function-related genes are primary.

**Materials and Methods**

**Animals and drug delivery.** All animal experiments in this study were approved by the Keio University Institutional Animal Care and Use Committee (09088) and were carried out in accordance with the Institutional Guidelines on Animal Experimentation at Keio University. Five-week-old male DS rats were purchased from Sankyo Labo Service Corporation, Inc. (Tokyo, Japan). The rats were divided into four groups: control [normal-salt diet containing 0.3% NaCl, NS (−)], normal-salt diet with chaetocin [0.25 mg/kg of chaetocin (Sigma-Aldrich Co. LLC., St. Louis, MO, USA), NS (ch+)], HF [high-salt diet containing 8% NaCl, HS (−)], and treatment [high-salt diet with 0.25 mg/kg of chaetocin, HS (ch+)] group. Chaetocin was dissolved in dimethyl sulfoxide (DMSO). Rats in the treatment group were administered 0.25 mg/kg of chaetocin intraperitoneally twice a week from 6 weeks of age until 13 weeks of age, as previously reported. Animals were sacrificed, and tissues were stored appropriately for individual experiments.

**Blood pressure and echocardiographic evaluations.** Blood pressure levels were measured at 5, 8, 10, and 13 weeks using the tail-cuff method (BP-98 A-L; Softron, Tokyo, Japan). Hearts of 13-week-old rats were evaluated by echocardiography using a VisualSonics (Vevo 2100; VisualSonics Inc.). Detailed procedures for blood pressure measurements and echocardiographic evaluations are given in the Supplemental Methods.

**Morphometric analysis.** Heart tissue was fixed in formalin, embedded in paraffin, and cut into 5–μm-thick sections. Sections were stained with hematoxylin-eosin or with EvG and picrosirius red to examine morphology and identify cardiac fibrosis. To evaluate collagen fiber quantity, the sections were observed using a fluorescence microscope (BZ-9000; KEYENCE Japan Inc. Osaka, Japan). The fibrotic volume fraction was assessed as the total fibrotic area (calculated by a cell-count system) divided by the total LV volume multiplied by 100.

**Quantitative real-time polymerase chain reaction (PCR).** Double-stranded cDNA was synthesized from 2 μg RNA and subjected to PCR with TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and predesigned gene-specific primer and probe sets (TaqMan Gene Expression Assays: Applied Biosystems). Detailed procedures for real-time quantitative PCR are given in the Supplemental Methods.

**DNA microarray.** RNA was extracted from LV samples in rats at the stage of heart failure using mirVana (Applied Biosystems), according to the manufacturer’s instructions. A mixture of RNA from three samples randomly chosen in each group was applied for genome-wide gene expression analysis using a Rat Oligo chip 20 K (Applied Biosystems). Detailed procedures for the read alignments are given in the Supplemental Methods.

**ChIP.** One gram of LV tissue per group was applied to ChIP with 25 μg antibody (targeting trimethylated K4 of histone H3 [#8580; Abcam, Tokyo, Japan] or trimethylated K9 of histone H3 [#07–442; Millipore, Temecula, CA, USA]), or 1 μg rabbit IgG (#2729; Cell Signaling Technology, Danvers, MA, USA). Detailed procedures for ChIP are given in the Supplemental Methods. In this paper, only the results of ChIP against trimethylated K9 of histone H3 are shown.

**Sequencing.** Precipitated DNA fragment samples were further fragmented prior to sequence analysis (HiSeq 2000). Chromatin immunoprecipitated (ChIP) genomic DNA from each group and input DNA were sequenced according to the manufacturer’s instructions (Illumina). Additional details of the read alignments are given in the Supplemental Methods.

**Alteration of H3K9me3 level at the repetitive elements.** We aligned the H3K9me3-ChIP’d reads to genomic features using both the rn4 assembly of the rat genome and a database of rat repetitive elements from the UCSC RepeatMasker track. If the ratio of nucleotide number overlapping between repetitive elements and sequenced reads to minimum number of nucleotides in the repetitive element or in the sequenced read was 90% or more, we considered it to be “overlapped”. We identified H3K9me3-enriched-regions on repetitive elements as those having 100-fold differences in H3K9me3 relative to input DNA.

**Isolation of heart mitochondria.** Mitochondria were freshly isolated from 13-week-old hearts, as described previously. Additional details are given in the Supplemental Methods.

**Mitochondrial oxygen consumption.** Mitochondrial oxygen consumption (mitochondrial respiration) was measured with a Clark-type O2 electrode using the Oxygen Meter Model 781 and the Mitocell MT200 closed respiratory chamber (Strathkelvin Instruments) at 37°C, as described previously. Additional details are given in the Supplemental Methods.

**Mitochondrial protein and DNA content.** The protein concentrations in mitochondrial fractions were measured using BCA protein assays. Mitochondrial DNA isolated from the heart was analyzed by real-time
quantitative PCR using a Thermal Cycler Dice Real Time System TP800 (Takara Bio Inc., Shiga, Japan). All samples were normalized to genomic DNA content. Primer and probe sequences for each PCR are shown in Supplemental Table 2.

**Statistical analysis.** The cumulative survival rates of rats in the different groups were compared using log-rank tests. All results are presented as means and standard deviations (SDs). Statistical comparisons were carried out using one-way analysis of variance (ANOVA) with post-Bonferroni corrections for Figs 1A–D and 4 and with post-hoc Dunnett corrections for Fig. 2B–D.

**Data deposition.** Microarray data and ChIP-seq data are deposited in GEO with accession numbers GSE66617 and GSE69194.

**References**

1. Gaddam, K. K. & Ventura, H. Developments in heart failure 2011. *Congest Heart Fail* 18, 112–126 (2012).
2. Roger, V. L. Epidemiology of heart failure. *Circ Res* 113, 646–659 (2013).
3. Packer, M. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med* 334, 1349–1355 (1996).
4. Packer, M. et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 344, 1651–1658 (2001).
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *Lancet* 353, 2001–2007 (1999).
6. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. *N Engl J Med* 316, 1429–1435 (1987).
7. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med* 325, 293–302 (1991).
8. Vancy, C. W. et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 128, e240–327 (2013).
9. Barth, A. S. et al. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. *J Am Coll Cardiol* 48, 1610–1617 (2006).
10. Colak, D. et al. Left ventricular global transcriptional profiling in human end-stage dilated cardiomyopathy. *Genomics* 94, 20–31 (2009).
11. Grzeskowiak, R. et al. Expression profiling of human idiopathic dilated cardiomyopathy. *Cardiovasc Res* 59, 400–411 (2003).
12. Yung, C. K., Halperin, V. L., Tomasselli, G. F. & Winslow, R. L. Gene expression profiles in end-stage human idiopathic dilated cardiomyopathy: altered expression of apoptotic and cytoskeletal genes. *Genomics* 83, 281–297 (2004).
13. Barranz, J. D., Allen, P. D., Stamatou, D., Dzau, V. J. & Liew, C. C. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. *Am J Pathol* 160, 2035–2043 (2002).
14. Asakura, M. & Kitakaze, M. Global gene expression profiling in the failing myocardium. *Circ J* 73, 1568–1576 (2009).
15. Campos, E. I. & Reinberg, D. Histones: annotating chromatin. *Annu Rev Genet* 45, 559–599 (2009).
16. Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. *Cell* 110, 479–488 (2002).
17. Wei, J. Q. et al. Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. *Circulation* 118, 934–946 (2008).
18. Cardinales, J. P. et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. *Hypertension* 56, 437–444 (2010).
19. McKinsey, T. A. Therapeutic potential for HDAC inhibitors in the heart. *Annu Rev Pharmacol Toxicol* 52, 303–319 (2012).
20. Lee, H. J. & Kook, H. Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. *J Mol Cell Cardiol* 47, 778–780 (2009).
21. Glenn, D. J., Wang, F., Chen, S., Nishimoto, M. & Gardner, D. G. Endothelin-stimulated human B-type natriuretic peptide gene expression is mediated by Yin Yang 1 in association with histone deacetylase 2. *Hypertension* 53, 549–555 (2009).
22. Gao, D. J. et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. *Proc Natl Acad Sci USA* 108, 4123–4128 (2011).
23. Zhang, L. Y. et al. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylation inhibition. *Am J Physiol Heart Circ Physiol* 298, H2154–2163 (2010).
24. Kong, Y. et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. *Circulation* 113, 2579–2588 (2006).
25. Barter, M. J. et al. HDAC-mediated control of ERK- and PI3K-dependent extracellular matrix-regulating genes. *Matrix Biol* 29, 602–612 (2010).
26. Iyer, A. et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. *Br J Pharmacol* 159, 1408–1417 (2010).
27. Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. *Nat Med* 13, 1299–1307 (2007).
28. Samant, S. A. et al. HDAC3-dependent reversible lysine acetylation of cardiac myosin heavy chain isoforms modulates their enzymatic and motor activity. *J Biol Chem* 286, 5567–5577 (2011).
29. Kaneda, R. et al. Genome-wide histone methylation profile for heart failure. *Genes Cells* 14, 69–77 (2009).
30. Movassagh, M. et al. Distinct epigenetic features in end-stage failing human hearts. *Circulation* 124, 2411–2422 (2011).
31. Hohl, M. et al. HDAC4 controls histone methylation in response to elevated cardiac load. *J Clin Invest* 123, 1339–1370 (2013).
32. Zhang, Q. J. et al. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. *J Clin Invest* 121, 2474–2485 (2011).
33. Stein, A. R. et al. Loss of H3K4 methylation destabilizes gene expression patterns and physiological functions in adult murine cardiomyocytes. *J Clin Invest* 121, 2641–2650 (2011).
34. Schotta, G. et al. Central role of Drosophila SU(VAR)3-9 in histone H3-K9 methylation and heterochromatin gene silencing. *EMBO J* 21, 1121–1131 (2002).
35. Sree, R. B. et al. Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability. *Onco rape* 31, 3244–3253 (2012).
36. Hunter, G. G. et al. Acute stress and hippocampal histone H3 lysine 9 trimethylation, a retrotransposon silencing response. *Proc Natl Acad Sci USA* 109, 17657–17662 (2012).
37. Hauser, D., Weber, H. P. & Sigg, H. P. [Isolation and configuration of Chaetocin]. *Helv Chim Acta* 53, 1061–1073 (1970).
38. Greiner, D., Bonadil, T., Eskeland, R., Roemer, E. & Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. *Nat Chem Biol* 1, 143–145 (2005).
39. Chan, P. K. et al. Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3. *Hum Mol Genet* 22, 2662–2675 (2013).
40. Asano, T. et al. LamI functional retropropox causes right ventricular dysplasia in mice. *Nat Genet* 36, 123–130 (2004).
41. Matsubara, Y. et al. Molecular cloning of cDNAs encoding rat and human medium-chain acyl-CoA dehydrogenase and assignment of the gene to human chromosome 1. Proc Natl Acad Sci USA 83, 6543–6547 (1986).
42. Jonassen, T. & Clarke, C. F. Isolation and functional expression of human COQ3, a gene encoding a methyltransferase required for ubiquinone biosynthesis. J Biol Chem 275, 12381–12387 (2000).
43. Papa, S. The NDUF54 nuclear gene of complex I of mitochondria and the cAMP cascade. Biochim Biophys Acta 1555, 147–153 (2002).
44. Cherblanc, F., Chapman, K., Brown, R. & Fuchter, M. Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol 9, 136–137 (2013).
45. Takahashi, M. et al. Inhibition of histone H3K9 methyltransferases by gliotoxin and related epipolythiodioxopiperazines. J Antibiot 65, 263–265 (2012).
46. Isham, C. R. et al. Chaetocin: a promising new antitumor agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 109, 2579–2588 (2007).
47. Nogales-Cadenas, R. et al. Genecodis: Interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res 37, W317–322 (2009).
48. Tabas-Madrid, D., Nogales-Cadenas, R. & Pascual-Montano, A. Genecodis3: A non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res 40, W478–483 (2012).
49. Carmona-Saez, P., Chagoyen, M., Tirado, F., Carazo, J. M. & Pascual-Montano, A. Genecodis: A web-based tool for finding significant concurrent annotations in gene lists. Genome Biol 8, R3 (2007).
50. Endo, J. et al. Metabolic remodeling induced by mitochondrial aldehyde stress stimulates tolerance to oxidative stress in the heart. Circ Res 105, 1118–1127 (2009).
51. Wolf, A. M. et al. Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. J Nutr Biochem 21, 381–389 (2010).

Acknowledgements
The authors thank Drs Kuniaki Saito, and Yuka W. Iwasaki for helpful suggestions; Mr. Yukiteru Ono for bioinformatic support; and Ms. Yoshiko Miyake, Ms. Kunika Suzuki, Ms. Moeka Suzuki, and Ms. Harumi Ichimiya for technical assistance. This work was supported by grants to R.K. from JST, PRESTO, MEXT (#21790747), Japan Heart Foundation Novartis Research Award on Molecular and Cellular Cardiology, and the Nateglinide Memorial Toyoshima Research and Education Fund and by a grant to T.O. from the Keio University Doctorate Student Grant-in-Aid Program.

Author Contributions
R.K. designed the research. T.O., N.K., T.M., T.N., T.N., J.E., T.H., T.N., N.S., and R.K. performed the research. H.T., S.O., M.S., M.I., M.S., K.F., and R.K. analyzed the data. T.O., N.K., and R.K. wrote the paper.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Ono, T. et al. The histone 3 lysine 9 methyltransferase inhibitor chaetocin improves prognosis in a rat model of high salt diet-induced heart failure. Sci. Rep. 7, 39752; doi: 10.1038/srep39752 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017